Diagnostic screening programs help catch cancer, abnormalities or other diseases before they reach an advanced stage, saving lives and healthcare costs. Screening programs include, lung, breast, prostate, and cervical cancer, among many others.
Though the study of AI in lung cancer screening is not new, prior research has been retrospective in nature, making it challenging to determine the impact.
Mandates for universal ECG screening are gaining momentum as a way to combat the risk of SCA. However, the ACC warned, modern healthcare systems were not built to withstand such a rise in demand. These mandates will also result in higher costs and other unintended consequences.
There are no standards requiring radiologists to report on the presence of BACs, even though up to half of referring providers have indicated they would prefer to be made aware of the finding.
Breast artery calcifications are already visible when radiologists review mammograms, but nothing typically happens with them. Researchers aimed to see if AI could help translate those findings into an easy-to-understand cardiovascular risk score.
Despite the great progress that has been made toward the clinical implementation of AI, new data caution against trusting the technology as a single reader in certain settings.
The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.
Ultrasound is routinely used to screen for HCC. However, its utility is limited by numerous factors, including patient body habitus, operator experience and certain liver conditions, all of which contribute to decreases in sensitivity.